Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
480 Study of Locteron versus PEG-Intron plus ribavirin in treatment-naive genotype 1 hepatitis C
2009-011182-86Phase 2Completed
- Sponsor
- Biolex Therapeutics
- Start
- Jul 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of interferon alfa-2b in hepatitis C virus infection (2 arms), sponsored by Biolex Therapeutics. Primary endpoint: Early virologic response. Started Jul 2009; status: completed.
02
Drugs
interferon alfa-2b
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-011182-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011182-86.